Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled Phase III Study of Amisulpride for IV Injection as Prophylaxis Against Post-operative Nausea and Vomiting

NCT05822713 is registered in ClinicalTrials.gov with Qilu Pharmaceutical (Hainan) Co., Ltd. as lead sponsor.

NCT NCT05822713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05822713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled Phase III Study of Amisulpride for IV Injection as Prophylaxis Against Post-operative Nausea and Vomiting
Lead sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
April 29, 2023
Completion date
December 31, 2023
Enrollment
516 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ponv